Search for: [Abstract = "The aim of trial was assessment of\: 1\) prognostic value of HER2 receptor and 2\) predictive value in adjuvant chemotherapy \(CMF vs. anthracycline\-containing schedules\), and 3\) adjuvant hormonal therapy \(only with tamoxifen vs. aromatase inhibitors\-based therapy\), in women with initially operable breast cancer by analyzing the effect of HER2 status assessed with the immunohistochemical method \(IHC\) on the probability of 5\- and 10\-year overall and disease\-free survival \(5y\/10yOS and 5y\/10yDFS, respectively\). The study was performedon group of 391 women operated due to breast cancer from 01.01.1994 in University Hospital in Cracow, and then treated with adjuvant therapy, or observed \/follow\-up only. The observation of all patients \(pts\) was completed on the 31.12.2010. The 0, 1\+ and 2\+ levels of HER2 receptor expression were scored as the normal expression, whereas 3\+ level as overexpression. HER2 receptor overexpression was observed in a total of 69 pts \(17.6%\). It was demonstrated\: 1\) in one\-way ANOVA that HER2 overexpression reduces DFS \(HER2 0, 1\+, 2\+\: 5yDFS\-78.3%, 10yDFS\-60.2% vs. HER2 3\+\: 5yDFS\-62.7%, 10yDFS\-31.6%\; p<0.001\)\; 2\) in two\-way ANOVA that progression risk was higher \(HR 1.87, 95% CI 1.21\-2.90\) in pts with overexpression\; 3\) in the survival analysis that HER2 overexpression in pts treated with tamoxifen only reduced the percentage of 5yOS by ca. 20% \(HER2 0, 1\+, 2\+\: 5yOS\-90.8% vs. HER2 3\+\: 5yOS\-69.3%\; p=0.003\), that of 10yOS by ca. 30% \(HER2 0, 1\+, 2\+\: 10yOS\-84.4% vs. HER2 3\+\: 10yOS\-54.8%\; p=0.003\), and that of 5y and 10yDFS by ca. 40% \(5yDFS\-85.1%, 10yDFS\-69.4% vs. 5yDFS\-47.4%, 10yDFS\-31.6%, p<0.001\)."]

Number of results: 0